Fundraising Fox

Blaze Bioscience

Seattle, US · Founded 2010 · Delaware corporation · 1 known investors

blazebioscience.com
Biotech

Founders & leadership

HL
Heather L. FranklinDirector
SR
Steven R. DalyExecutive Officer, Director
LR
Ludmila R. LobanovaExecutive Officer
JN
Julia NovakExecutive Officer
LL
Ludmila LobanovaExecutive Officer
JM
James M. OlsonDirector
JO
Jan OhrstromDirector
ME
Mary Ellen HughesDirector
DM
Dennis M MillerExecutive Officer
JC
James C. TowneExecutive Officer, Director
LP
Lawrence Patrick HughesDirector
JK
Jan K. OhrstromDirector

Investors · 1

Competitors · 5

by search overlap
Precision BioSciences13 shared keywordsPrecision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform. Note: the page content provided contains only a cookie consent notice, so this description reflects the company's known focus rather than the extracted text.
Cowles_Investments_StemCentrx11 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Castle Biosciences10 shared keywordsCastle Biosciences develops genomic tests that provide personalized biological information to inform disease diagnosis, treatment selection, and follow-up care decisions for healthcare providers and patients. The company operates in precision genomics and clinical diagnostics focused on improving patient outcomes.
Life Biosciences9 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
PatSnap9 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.

Companies competing with Blaze Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
$15MraisedOct 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jan K. OhrstromDirector
  • Steven R. DalyExecutive Officer, Director
  • James C. TowneExecutive Officer, Director
  • Lawrence Patrick HughesDirector
  • Heather L. FranklinDirector
  • Ludmila R. LobanovaExecutive Officer
Offering amount
$15M
Amount sold
$15M
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$10MraisedOct 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jan K. OhrstromDirector
  • Heather L. FranklinDirector
  • Ludmila R. LobanovaExecutive Officer
  • Steven R. DalyExecutive Officer, Director
  • James C. TowneExecutive Officer, Director
  • Lawrence Patrick HughesDirector
Offering amount
$10M
Amount sold
$10M
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$8.1MraisedOct 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Heather L. FranklinDirector
  • Steven R. DalyExecutive Officer, Director
  • Lawrence Patrick HughesDirector
  • James C. TowneExecutive Officer, Director
  • Ludmila R. LobanovaExecutive Officer
  • Jan K. OhrstromDirector
Offering amount
$20M
Amount sold
$8.1M
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$25MraisedOct 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven R. DalyExecutive Officer, Director
  • Heather L. FranklinDirector
  • Jan K. OhrstromDirector
  • James C. TowneExecutive Officer, Director
  • Ludmila R. LobanovaExecutive Officer
  • Lawrence Patrick HughesDirector
Offering amount
$25M
Amount sold
$25M
First sale
Oct 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$20.2MraisedApr 2020 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Claudia JochheimExecutive Officer
  • Jan Koch OhrstromDirector
  • Dennis MillerExecutive Officer
  • Mary Ellen HughesDirector
  • Ludmila LobanovaExecutive Officer
  • Heather FranklinExecutive Officer, Director
  • James Cameron TowneDirector
Offering amount
$25.2M
Amount sold
$20.2M
First sale
Feb 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$3MraisedMay 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAN OHRSTROMDirector
  • CLAUDIA JOCHHEIMExecutive Officer
  • DENNIS MILLERExecutive Officer
  • MARY ELLEN HUGHESDirector
  • HEATHER FRANKLINExecutive Officer, Director
  • LUDMILA LOBANOVAExecutive Officer
  • JAMES C. TOWNEDirector
Offering amount
$5M
Amount sold
$3M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$16.1MraisedOct 2017 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • LUDMILA LOBANOVAExecutive Officer
  • MARY ELLEN HUGHESDirector
  • HEATHER FRANKLINExecutive Officer, Director
  • JAN OHRSTROMDirector
  • JAMES C. TOWNEDirector
  • DENNIS MILLERExecutive Officer
Offering amount
$18.1M
Amount sold
$16.1M
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$554KraisedJun 2017 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES C. TOWNEDirector
  • MARY ELLEN HUGHESDirector
  • LUDMILA LOBANOVAExecutive Officer
  • JAN OHRSTROMDirector
  • DENNIS MILLERExecutive Officer
  • HEATHER FRANKLINExecutive Officer, Director
Offering amount
$5M
Amount sold
$554K
First sale
Jun 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2014$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$248.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.